KVUE · Kenvue Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · KVUE

1Y 3Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$15.12B	$15.46B	$15.44B	$7.42B◇	$5.64B◇	-
Cost of Revenue	$6.33B	$6.50B	$6.63B	-	-	-
Gross Profit	$8.79B	$8.96B	$8.42B	$8.29B◇	$8.42B◇	-
R&D	$382.00M	$408.00M	$399.00M	-	-	-
SG&A	$6.09B	$6.33B	$5.48B	$547.00M◇	$0◇	-
Total Operating Expenses	-	-	-	-	-	-
D&A	$557.00M	$622.00M	$644.00M	-	-	-
Operating Income	$2.41B	$1.84B	$2.92B	$2.67B◇	$2.92B◇	-
Interest Expense	$430.00M	$431.00M	$0	$0◇	$0◇	-
Income Tax	$529.00M	$385.00M	$847.00M	$573.00M◇	($47.00M)◇	-
Net Income	$1.47B	$1.03B	$2.06B	$2.06B◇	$2.03B◇	-
EPS - Basic	$0.77	$0.54	$1.21	$1.20◇	$1.21◇	-
EPS - Diluted	$0.76	$0.54	$1.20	$1.20◇	$0.03◇	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$1.06B	$1.07B	$1.38B	$1.23B◇	-	-
Accounts Receivable	$2.38B	$2.17B	$2.07B	-	-	-
Inventory	$1.67B	$1.59B	$1.85B	-	-	-
Accounts Payable	$2.47B	$2.25B	$2.49B	-	-	-
Current Assets	$5.70B	$5.53B	$6.14B	$5.88B◇	-	-
Total Assets	$27.08B	$25.60B	$27.85B	$27.32B◇	-	-
Current Liabilities	$5.95B	$5.74B	$5.48B	$3.93B◇	-	-
Long-term Debt	-	-	$7.69B	$0◇	-	-
Total Liabilities	$16.31B	$15.93B	$16.64B	$7.35B◇	-	-
Stockholders' Equity	$10.77B	$9.67B	$18.40B	$0◇	$0◇	$21.93B◇
Retained Earnings	($204.00M)	($93.00M)	$429.00M	-	-	-

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$2.20B	$1.77B	$3.17B	$2.52B◇	$334.00M◇	-
Investing Cash Flow	($436.00M)	($425.00M)	($390.00M)	($390.00M)◇	($171.00M)◇	-
Financing Cash Flow	($1.84B)	($1.56B)	$0	($1.58B)◇	$0◇	-
CapEx	$475.00M	$434.00M	$375.00M	$375.00M◇	$295.00M◇	-
Free Cash Flow	$1.72B	$1.33B	$2.79B	$2.15B◇	$39.00M◇	-

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	58.1%	58.0%	54.5%	111.7%	149.2%	-
Operating margin	16.0%	11.9%	18.9%	36.1%	51.7%	-
EBITDA margin	19.6%	15.9%	23.1%	-	-	-
Net margin	9.7%	6.7%	13.4%	27.8%	36.0%	-
Free cash flow margin	11.4%	8.6%	18.1%	29.0%	0.7%	-
FCF / Net income	1.17	1.30	1.35	1.04	0.02	-
R&D / Revenue	2.5%	2.6%	2.6%	-	-	-
SG&A / Revenue	40.3%	41.0%	35.5%	7.4%	0.0%	-
Effective tax rate	26.5%	27.2%	29.1%	21.7%	-2.4%	-
Return on assets	5.4%	4.0%	7.4%	7.6%	-	-
Return on equity	13.7%	10.7%	11.2%	-	-	-
Return on invested capital	-	-	7.9%	-	-	-
Liquidity
Current ratio	0.96	0.96	1.12	1.50	-	-
Quick ratio	0.68	0.69	0.78	1.50	-	-
Cash ratio	0.18	0.19	0.25	0.31	-	-
Leverage
Debt / Equity	-	-	0.42	-	-	-
Debt / Assets	-	-	0.28	0.00	-	-
Debt / EBITDA	-	-	2.16	-	-	-
Interest coverage	5.6x	4.3x	-	-	-	-
Equity multiplier	2.52	2.65	1.51	-	-	-
Liabilities / Assets	0.60	0.62	0.60	0.27	-	-
Efficiency
Asset turnover	0.56	0.60	0.55	0.27	-	-
Inventory turnover	3.80	4.08	3.58	-	-	-
Days sales outstanding	57d	51d	49d	-	-	-
Days inventory outstanding	96d	89d	102d	-	-	-
Days payable outstanding	143d	127d	137d	-	-	-
Cash conversion cycle	11d	14d	14d	-	-	-
Valuation
P / E	22.7x	39.5x	17.9x	-	-	-
P / B	3.1x	4.2x	2.2x	-	-	-
P / S	2.2x	2.7x	2.6x	-	-	-
EV / EBITDA	10.8x	16.2x	12.9x	-	-	-
Growth
Revenue growth (YoY)	-2.1%	0.1%	108.2%	31.5%	-	-
Revenue CAGR (3y)	26.8%	39.9%	-	-	-	-
Revenue CAGR (5y)	-	-	-	-	-	-
Gross profit growth (YoY)	-1.9%	6.4%	1.6%	-1.6%	-	-
Operating income growth (YoY)	31.1%	-37.0%	9.2%	-8.4%	-	-
Net income growth (YoY)	42.7%	-50.1%	0.0%	1.6%	-	-
EPS growth (YoY)	40.7%	-55.0%	0.0%	3900.0%	-	-
EPS CAGR (3y)	-14.1%	162.1%	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	29.0%	-52.2%	29.9%	5412.8%	-	-
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	11.3%	-47.5%	-	-	-	-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-28.

Business segments

$15.12B total

Self Care$6.38B · 42.2%

Essential Health$4.63B · 30.6%

Skin Health And Beauty$4.11B · 27.2%

Geographic

$21.58B total

North America$7.26B · 33.6%

US$6.46B · 29.9%

EMEA$3.72B · 17.2%

Asia Pacific$2.77B · 12.9%

Latin America$1.37B · 6.3%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

1.10

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

6/9

Neutral

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✓No share dilution
✓Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations

Company	Revenue (last FY)	Net margin	ROE
EL	$14.33B	-7.9%	-29.3%
CL	$20.38B	10.5%	3948.1%
ELF	$1.64B	1.6%	2.3%
EPC	$2.22B	1.1%	1.6%
COTY	$5.89B	-6.2%	-10.4%

Comparing Kenvue Inc. against the 5 most active filers in the same SIC group.

Dividends

$0.83/share trailing 12 months · +1.5% YoY

Ex-date	Per share
May 13, 2026	$0.2080
Feb 11, 2026	$0.2080
Nov 12, 2025	$0.2080
Aug 13, 2025	$0.2080
May 14, 2025	$0.2050
Feb 12, 2025	$0.2050
Nov 13, 2024	$0.2050
Aug 14, 2024	$0.2050
May 7, 2024	$0.2000
Feb 13, 2024	$0.2000
Nov 7, 2023	$0.2000
Aug 25, 2023	$0.2000

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.